Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies

Inclusion Criteria:

• Definite diagnosis of malignant hematologic disease before transplantation, age 12-60 years old, gender is not limited, race is not limited;

• Patients who are proposed to receive allo-PBSCT for the first time;

• Eastern Cooperative Oncology Group (ECOG) score 0-2;

• No serious organ failure and active infection;

• Voluntary open randomized controlled study to observe whether the time of stem cellinfusion affects the occurrence of aGVHD after transplantation;

• Each subject must sign an informed consent form (ICF) indicating that he/sheunderstands the purpose and procedures of the study and is willing to participate inthe study; in view of the patient's condition, if the patient's own signature is notconducive to the treatment of his/her condition, the ICF will be signed by the legalrepresentative.

Exclusion Criteria:

• Those with severe organ dysfunction or disease, such as severe disease anddysfunction of the heart, liver, kidneys and pancreas;

• Pregnant patients;

• Patients and/or authorized family members who refuse to undergo an open randomizedcontrolled study to observe whether the time of stem cell infusion affects theoccurrence of aGVHD after transplantation;

• Any life-threatening disease, physical condition, or organ system dysfunction that,in the opinion of the investigator, may compromise patient safety and put theresults of the study at unnecessary risk; drug-dependent individuals; patients withuncontrolled psychiatric disorders; and individuals with cognitive dysfunction;

• Participants in other clinical studies that may affect aGVHD within 3 months;

• Those whom the investigator considers unsuitable for enrollment (e.g., those whoanticipate that patients will not be able to adhere to the examination and treatmentdue to financial and other issues).